ArticleBritish journal of clinical pharmacology2025

A single-centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease.

Louise Rabbitt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.